You are currently viewing the summary.
View Full TextVia AAAS ID
This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.
Summary
A huge toll of illness and death, a dire need for new treatments, and rapid scientific progress are inspiring researchers to battle malaria. But most drug companies balk at investing in what they see as a Third World disease. Some researchers think it's time for the government to step in, perhaps with tax breaks and longer patents for certain drugs on the condition that the revenue be used for new antimalarials.
